|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-6-12
|
|
pubmed:abstractText |
To determine the long-term antiretroviral efficacy and tolerability of dual protease inhibitor (PI) therapy with indinavir (IDV)/ritonavir (RTV) at 400/400 mg twice a day (BID) in combination with two nucleoside reverse trancriptase inhibitors (NRTIs).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1464-2662
|
|
pubmed:author |
pubmed-author:BergmannFF,
pubmed-author:CarlsHH,
pubmed-author:FätkenheuerGG,
pubmed-author:FenskeSS,
pubmed-author:KnechtenHH,
pubmed-author:LichterfeldMM,
pubmed-author:NadlerMM,
pubmed-author:NischalkeH DHD,
pubmed-author:OetteMM,
pubmed-author:RiekeAA,
pubmed-author:RockstrohJ KJK,
pubmed-author:TheisenAA,
pubmed-author:WasmuthJ-CJC,
pubmed-author:WieselWW
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
37-43
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12059949-Adult,
pubmed-meshheading:12059949-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12059949-CD8-Positive T-Lymphocytes,
pubmed-meshheading:12059949-Drug Therapy, Combination,
pubmed-meshheading:12059949-Female,
pubmed-meshheading:12059949-Flow Cytometry,
pubmed-meshheading:12059949-HIV Infections,
pubmed-meshheading:12059949-HIV Protease Inhibitors,
pubmed-meshheading:12059949-HIV-1,
pubmed-meshheading:12059949-Humans,
pubmed-meshheading:12059949-Indinavir,
pubmed-meshheading:12059949-Male,
pubmed-meshheading:12059949-Middle Aged,
pubmed-meshheading:12059949-RNA, Viral,
pubmed-meshheading:12059949-Retrospective Studies,
pubmed-meshheading:12059949-Reverse Transcriptase Inhibitors,
pubmed-meshheading:12059949-Ritonavir,
pubmed-meshheading:12059949-Viral Load
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
|
|
pubmed:affiliation |
Department of General Internal Medicine, University of Bonn, Berlin, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Multicenter Study
|
